Development

A patient-specific mRNA vaccine wins the first Phase 3 in oncology

development2026-08-19

Claim

Merck and Moderna's mRNA vaccine, written from each patient's tumor, cut recurrence and metastasis in 1,137 melanoma patients, the first Phase 3 win for mRNA in oncology.

Reported metric: 1,137 patients

Reporting date: 2026-08-19 (not necessarily the event date)

Sources

Attribution and reporting linked by this record; links do not imply independent verification.

Welcome to August 19, 2026 (theinnermostloop.substack.com)

Knowledge graphopen in browser →

Reported in

Welcome to August 19, 2026

Actor

Evidence for

Supersedes

A regulator approves the first US mRNA flu vaccine

Referenced by

Welcome to August 19, 2026

Cite or correct this record

Citation formatCitation text

A patient-specific mRNA vaccine wins the first Phase 3 in oncology
Innermost Loop KB — secondary record
Reporting date: 2026-08-19
KB permalink: https://nicholsn.github.io/innermost-loop-kb/developments/2026-08-19-the-first-phase-three-mrna-win-in-oncology
Claim: Merck and Moderna's mRNA vaccine, written from each patient's tumor, cut recurrence and metastasis in 1,137 melanoma patients, the first Phase 3 win for mRNA in oncology.
Attributed sources:
- Welcome to August 19, 2026 — https://theinnermostloop.substack.com/p/welcome-to-august-19-2026
This citation does not imply independent verification of linked-source claims.

Suggest a correction — opens a GitHub draft for you to review and submit.